

ASX Release

TALi Digital Board Update

TALi Digital Ltd (ASX:TD1, "TALi" or "the Company") a leading health technology business seeking to improve attention in early childhood, today updates the Board membership, welcoming Dr David Brookes as Non-Executive Director and announcing the resignation of Mark Simari.

TALi Digital Managing Director, Glenn Smith, said: "We are delighted to welcome Dr Brookes to the Board, as he brings a wealth of clinical experience as well as commercial experience in the health technology sector. Dr Brookes' expertise and networks will complement the TALi leadership team, particularly as we extend our commercial footprint in the world's largest digital health markets."

Dr. Brookes has extensive experience in the health and biotechnology industries, first becoming involved in the biotechnology sector in the late 1990's as a consultant. Dr. Brookes has since held Board positions in numerous ASX listed biotechnology companies, including Chairman of genomics solutions company, RHS Ltd, which was acquired by PerkinElmer Inc (NYSE:PKI \$9B biotech company) in June 2018. He is currently a Non-Executive Director of Factor Therapeutics (ASX: FTT) and of Anantara Lifesciences Ltd (ASX:ANR); as well as Non-Executive Chairman of the Better Medical group (unlisted). Dr Brookes, MBBS (Adelaide), is a Fellow of the Australian College of Rural and Remote Medicine and a Fellow of the Australian Institute of Company Directors.

In accepting the board position Dr Brookes said: "From the moment I discovered the TALi products I understood the capability and global opportunity for this truly unique, evidence-based platform. It is with great excitement and determination that I join the TALi board to assist in making a real difference to the lives of children."

Mark Simari has now elected to complete his tenure with the board. In thanking Mr. Simari for his service to TALi Mr Smith said: "Mark has guided our business through an important period of development and contributed invaluable corporate management experience to the team. He has been paramount in the structure and capitalisation of TALi allowing the business to deliver on its commercialisation objectives and setting it up for future growth. We wish him every success in his new endeavours."

The Company will continue to seek further additions to the board primarily from international jurisdictions over the forward period as the Company continues its expansion strategy. Mr Simari's effective resignation date is 29th June 2020 and Dr Brookes' commencement date is 29th June 2020.

Release authorised by:

Glenn Smith
TALi Digital Managing Director

ABOUT TALi DIGITAL

TALi Digital Limited (ASX:TD1) a leading medical device and technology business is seeking to improve attention in early childhood through its breakthrough TALi platform. TALi combines evidence-based proprietary algorithms inside a game-based program to assess and strengthen core attention skills. Learn more at talihealth.com.

CONTACT

General + Investor Enquiries

Glenn Smith
TALi Digital Managing Director
p. 1300 082 013
e. investor@talihealth.com

Media enquiries

Haley Chartres
H^CK Director
p. +61 423 139 163
e. haley@hck.digital